LATEST ALERTS
PG/phytol research should come with a health warning – lab rats are not humans
19th March 2021 - News analysis |
Any conclusion drawn from studies on rodents must be treated with caution if we want to know about effects on humans
Health and science
Pregnant mice study touches on FDA questions, but more research is needed
12th March 2021 - News analysis |
The US Food and Drug Administration (FDA) has called for an exploration of the effects of CBD on certain vulnerable populations such as children and pregnant women as part of its consumer update
Jazz Pharmaceuticals buys Epidiolex manufacturer GW Pharma for $7.2bn
3rd February 2021 - News analysis |
GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn
Financial investments suggest a mood of optimism around CBD and cannabis
26th January 2021 - News analysis |
Renewed interest in financing of CBD and cannabis businesses could signal that investors are starting to be positive again about the future after companies seemingly weathered the worst of the storm in 2020
Dutch health ministry provides relief for UK patients forgotten in Brexit deal
25th January 2021 - News analysis |
Dutch officials have granted a six-month reprieve to find a solution to an omission in the Brexit negotiations that threatens to deprive British epilepsy patients of access to cannabis-based medicines
COVID-19: emergency regulations and affected legislative procedures
14th January 2021 - Regulatory alerts roundup |
Find all of CBD-Intel’s coronavirus-related regulatory alerts here, updated as they appear
It could have been so much worse: 2020 was CBD’s year in the waiting-room
1st January 2021 - News analysis |
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
Delay and dispute over deal to get CBD into Brazil’s public health system
30th December 2020 - News analysis |
Efforts to supply the first CBD product to Brazil’s public healthcare system will have to wait a while longer – and there is some dispute between the institute preparing to produce it and the sponsors of a Congress bill
I’m a celebrity – get me into quality cannabis, hemp and CBD brands…
23rd December 2020 - News analysis |
Increasing numbers of celebrities are endorsing CBD products, with names as big as will.i.am, Jay-Z, Beyoncé and Gwyneth Paltrow among those investing or launching their own brands
Avazo has its collar felt by the FDA/FTC over ‘unsubstantiated COVID-19 claims’
14th December 2020 - News analysis |
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
How far-reaching an impact could the CJEU Kanavape decision have?
11th December 2020 - Blogs |
The Court of Justice of the European Union’s (CJEU) decision in the Kanavape case will have a tremendous impact on the CBD industry in the European Union (EU). However, the breadth of its impact is not yet fully realised. A number of things must happen beforehand and it may come down to further court rulings before a baseline level of requirements and » Continue Reading.
Trials and research into the healing potential of cannabinoids continue
11th December 2020 - News analysis |
Pharmaceutical firms continue to invest in research into the healing potential of cannabinoids, launching clinical trials to investigate their ability to treat a range of conditions
Watchdog warns phony ‘research’ claims risk undermining consumer confidence
8th December 2020 - News analysis |
While solid research explaining the science behind CBD remains lacking as the market continues to grow, some bad actors in the industry are making false scientific claims for their products
What does the European Commissions (EC)’s change in opinion on CBD as a narcotic mean?
4th December 2020 - Blogs |
The announcement is a full reversal from the EC on a position that many found surprising in the first place. It marks a stellar period for the regulation of CBD and other cannabinoids with major decisions in their favour at the Court of Justice of the European Union, United Nations and now the EC. The resumption of novel food assessment » Continue Reading.
Canadian public and industry back plan to free CBD from cannabis regulation
1st December 2020 - News analysis |
The results of Canada’s public consultation on health products containing cannabis have been released, showing strong support for allowing the sale of CBD outside the current cannabis restrictions
The British isle heading for its own rules on cannabinoid extraction for export
1st December 2020 - News analysis |
The Isle of Man looks likely to become the second jurisdiction operating under UK regulations to allow the use of hemp flowers in extraction
What impact will Black Friday sales have on the CBD sector?
27th November 2020 - Blogs |
Overall it seems the industry – particularly in Europe – is not expecting much from Black Friday sales. European companies appear to consider CBD products more as health products that are requirement purchases throughout the year as opposed to lifestyle products that might be purchased as a one off during a special sales event. The situation may be slightly different in the US where Black Friday – » Continue Reading.
How important is the CJEU decision on the Kanavape case?
20th November 2020 - Blogs |
How important is the CJEU decision on the Kanavape case? The judgement in favour of CBD from the Courts of Justice of the European Union (CJEU) will almost certainly have significant long-term consequences for the CBD industry in Europe. It will likely influence the European Commission (EC)’s further assessment of the question of whether CBD is a narcotic. The preliminary opinion » Continue Reading.
The good, the bad and the troublesome – could CBD and nicotine make a match?
17th November 2020 - News analysis |
CBD, generally seen as a health or wellness product, and “bad guy” nicotine are almost opposites in terms of public perception – but could putting the two together make commercial sense?
Where are we most likely to see changes to medical and recreational cannabis regimes?
13th November 2020 - Blogs |
Mexico is overall the number one country to watch, rated highly likely to change regulations on both medical and recreational cannabis in the near future.
US FDA issues warning letter over COVID-19 health claims
30th October 2020 - News analysis |
The US Food and Drink Administration (FDA) has issued a warning letter to the CBD company For Our Vets over COVID-19 health claims
Do companies need toxicological study data included in UK Food Standards Agency (FSA) novel food applications for them to be validated?
9th October 2020 - Blogs |
There are still quite a few unanswered questions regarding the novel food application process under the FSA. Fortunately the requirement of having toxicological data
Mushrooms may be good for you – and firms hope that can be good for them too
6th October 2020 - News analysis |
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
Wellness trend pushes multiple launches in CBD space
2nd October 2020 - News analysis |
Increasing numbers of CBD businesses are marketing products that chime with the wellness trend and now even Playboy is launching a line of CBD products in the US that promise physical and mental benefits
Topicals status across top CBD markets
1st October 2020 - Presentations , Resources |
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
Hopes growing in Brazil for further legalisation of medical cannabis
28th September 2020 - News analysis |
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
ACI consortium approach to obtain safety data for CBD moves forward
25th September 2020 - News analysis |
The Association for the Cannabinoid Industry (ACI) will move forward with its consortium approach to obtaining toxicology and safety data for CBD with at least 15 companies having signed up and an undisclosed number still in discussion
Researchers suggest CBD could work with terpenes in COVID-19 treatment
14th September 2020 - News analysis |
Studies looking at the potential for CBD to treat or alleviate COVID-19 symptoms continue to progress – with one study hinting at promising results combining CBD with other terpene products
CBD industry steps up with funding for ValidCare’s vital liver function study
7th September 2020 - News analysis |
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
Pharma gets bigger with approval for new cannabinoid-based treatments
3rd September 2020 - News analysis |
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
Podcast: what can European markets do with CBD Novel Food applications?
2nd September 2020 - Podcasts , Resources |
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
Closures, bankruptcy and rescues – cannabinoid firms battle for survival
2nd September 2020 - News analysis |
The bankruptcy stories continue for cannabinoid firms in the US and Canada as businesses struggle to survive in turbulent times
Love Hemp and Mile High see silver lining in COVID-19 pandemic for UK CBD sales
25th August 2020 - News analysis |
Expansion plans by two major players suggest confidence in the future of the CBD market in the UK, with one anticipating a continuing rise in sales driven by reactions to the COVID-19 pandemic
Study identifies possible dangers of taking cannabinoids with other drugs
24th August 2020 - News analysis |
A comprehensive list of possible cannabinoid/drug interactions has been published for the first time by researchers at Penn State University in the US
What can be made of Canopy’s increased interest in functional ingredients?
21st August 2020 - Blogs |
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
Canopy Growth takes stride into sports nutrition with NFL superstar tie-up
19th August 2020 - News analysis |
Canadian cannabinoid firm Canopy Growth has signed a multi-year deal with NFL quarterback Patrick Mahomes as part of its advance into the sports nutrition market
Nanotechnology could improve the therapeutic potential of cannabinoids
13th August 2020 - News analysis |
Nanotechnology – referring to any kind of technology dealing in very small scales such as atomic, molecular or supramolecular – could improve some of the disadvantages of cannabinoids, such as solubility
US FDA provides cannabis researchers guidance on sources, testing and quality
12th August 2020 - News analysis |
Clinical research guidance from the US Food and Drug Administration (FDA) should provide further impetus for cannabis research, which is certain to have an impact on the CBD market
The entourage effect – absence of evidence, but no evidence of absence
11th August 2020 - News analysis |
Some recent research has cast doubt on the idea that cannabis compounds may be more effective when taken together
Studies suggest interesting potential for lesser known cannabinoids
7th August 2020 - News analysis |
New research into the therapeutic potential of lesser known cannabinoids is progressing with recent discoveries about a host of new compounds
Vaping may be best method of consumption for CBD bioavailability
6th August 2020 - News analysis |
Scientists are increasingly starting to study how differing methods of consumption can affect CBD bioavailability – the ability to enter your bloodstream and induce effects
HempFusion completes NDC registration for CBD topical products
31st July 2020 - News analysis |
Registration in the US FDA National Drug Code (NDC) Directory conveys significant benefits even if the FDA does not specifically approve these items as over-the-counter products, according to a CBD company
Unwelcome but unsurprising: industry reactions to FDA testing
25th July 2020 - News analysis |
The FDA’s recent report that fewer than half of the CBD products tested from US store shelves contain the amount of CBD on the label was unwelcome news
Zygel could still prove beneficial for Fragile X Syndrome sufferers
24th July 2020 - News analysis |
A proposed new path forward and extra information presented by Zynerba Pharmaceuticals has thus far not impacted the company’s stock price
FDA promises CBD testing as report shows many labels are inaccurate
24th July 2020 - News analysis |
The US FDA has criticised CBD products for inaccuracies in labelling the amount of CBD present in products and promised further testing for the sector in the near future
Now that novel food applications in Europe are delayed, what does enforcement look like?
10th July 2020 - Blogs |
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
How is the novel food status of CBD progressing in Europe?
3rd July 2020 - Blogs |
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
Italians turning to CBD in place of prescription drugs, research suggests
22nd June 2020 - News analysis |
The use of CBD-based products has reduced the consumption of prescription drugs in Italy, according to a discussion paper from an international economics think-tank
Researchers on safety and toxicity confident of hitting UK deadlines
19th June 2020 - News analysis |
An industry association study of the safety and toxicity of cannabinoids is expected to be completed in time to meet submission deadlines to keep CBD-containing food, beverage and supplement products on the UK market
Is this prime time for CBD subscription models to make a mark in the market?
11th June 2020 - News analysis |
Subscription services are a niche area of the CBD market that could benefit from the ongoing COVID-19 pandemic, providing companies with security and customers with a way to try new products without leaving home
